Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22152194 | 1.00 | KAT2B (0.37) | KAT2BSMN1; SMN2GAA | |
| SCHEMBL22122260 | 0.89 | SMN1; SMN2 (0.35) | SMN1; SMN2GAA | |
| SCHEMBL22122439 | 0.88 | SMN1; SMN2 (0.34) | SMN1; SMN2GAA | |
| SCHEMBL26673748 | 0.88 | NR1D1 (0.35) | SMN1; SMN2GAA | |
| SCHEMBL22122269 | 0.85 | SMN1; SMN2 (0.33) | SMN1; SMN2GAA | |
| SCHEMBL22122337 | 0.85 | SMN1; SMN2 (0.33) | SMN1; SMN2GAA | |
| SCHEMBL22122325 | 0.85 | SMN1; SMN2 (0.33) | SMN1; SMN2GAA | |
| SCHEMBL22156630 | 0.84 | SMN1; SMN2 (0.35) | KAT2BSMN1; SMN2GAA | |
| SCHEMBL22122390 | 0.84 | SMN1; SMN2 (0.32) | SMN1; SMN2GAA | |
| SCHEMBL30975268 | 0.81 | KAT2B (0.44) | KAT2BSMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200197391-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | Revolution Medicines, Inc. | 2020-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200197391-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | KRAS, NRAS, HRAS | KAT2B 3000/4885SMN1; SMN2 4348/4885GAA 3216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.